Search

Displaying results 6241 - 6250 of 6279 in total
  1. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB19323
    ApprovedWithdrawn

    This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.

  2. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB19324
    ApprovedWithdrawn

    This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.

  3. Drug

    Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole

    go.drugbank.com/drugs/DB19413
    Approved

    This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.

  4. Drug

    Human Embryonic Stem Cell-derived M Cell

    go.drugbank.com/drugs/DB15734
    Investigational

    CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection.

    Synonyms: M cells
  5. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    In addition, GC-376 displays potent activity against various coronaviruses such as feline, ferret, and mink M<sup>pro</sup> coronavirus[A219026,A219031,A219036,A219041]. … A prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036].

  6. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs). As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

  7. Drug

    Parathiazine

    go.drugbank.com/drugs/DB15978
    Investigational

    Mixtures: EMEGRAV B-6
  8. Drug

    OBI-3424

    go.drugbank.com/drugs/DB16057
    Investigational

    OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL

  9. Drug

    NNC-55-0396 free base

    go.drugbank.com/drugs/DB17037
    Experimental

    NNC-55-0396 is a T-type Ca(2+) channel inhibitor.[A253047]

    Synonyms: Cyclopropanecarboxylic acid, (1s,2s)-2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester
  10. Drug

    PRGN-3006

    go.drugbank.com/drugs/DB17229
    Investigational

    PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface

    Synonyms: PRGN-3006 UltraCAR-T, Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface